Golden Seeds
Bill Whitaker
Managing Director Co-Chair Life Science SectionGreen Park & Golf Ventures
Clay Heighten
Founding PartnerJR Garcia
PrincipalCarl Soderstrom
Founding PartnerGreenhouse Capital Partners
Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.
Eric Desai
PrincipalH.I.G. BioVentures
Enoch Kariuki
Vice PresidentHercules Technology Growth Capital Inc.
Janice Borque
Managing Director Life SciencesHorizon Technology Finance
Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.
Jerry Michaud
Hub Angels Investment Group
Randy Barko
MemberIliad Ventures
Steve Tsetsekos
General PartnerImpatient
Small biotechnology companies are developing half of all future medicines, some of which may not reach patients due to lack of funding from traditional investors.
Although health-related charities received more than $31B in contributions in 2013, many of the charities which support research do not work with for-profit biotech companies. They predominantly fund academic and non-profit institutions which typically conduct early research and discover around 10% of new medicines (for-profit companies discover the remaining 90%).
Impatient is a new kind of health-related charity. We will only fund medical trials with small biotech companies.
Our scientific advisors will select promising, unfunded, medical treatments. You choose which treatment to support and 100% of your donation is spent on testing.
If the treatment is successful, 100% of the future royalty that Impatient receives from the biotech company will support access to new medicines for people who cannot afford them.